305 related articles for article (PubMed ID: 11912261)
1. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
Goodman WG; Hladik GA; Turner SA; Blaisdell PW; Goodkin DA; Liu W; Barri YM; Cohen RM; Coburn JW
J Am Soc Nephrol; 2002 Apr; 13(4):1017-1024. PubMed ID: 11912261
[TBL] [Abstract][Full Text] [Related]
2. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
[TBL] [Abstract][Full Text] [Related]
3. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
5. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
[TBL] [Abstract][Full Text] [Related]
7. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
10. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
[TBL] [Abstract][Full Text] [Related]
11. The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.
Ohashi N; Uematsu T; Nagashima S; Kanamaru M; Togawa A; Hishida A; Uchida E; Akizawa T; Koshikawa S
Br J Clin Pharmacol; 2004 Jun; 57(6):726-34. PubMed ID: 15151518
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
14. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Akizawa T; Tsukamoto Y; Uchida E; Iwasaki M; Koshikawa S;
Ther Apher Dial; 2008 Apr; 12(2):117-25. PubMed ID: 18387159
[TBL] [Abstract][Full Text] [Related]
15. Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Goodman WG
Semin Nephrol; 2004 Sep; 24(5):460-3. PubMed ID: 15490411
[TBL] [Abstract][Full Text] [Related]
16. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
17. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
18. Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia.
Goodman WG; Ward DT; Martin KJ; Drayer D; Moore C; Xu J; Lai J; Chon Y; Nemeth EF
J Am Soc Nephrol; 2022 Jan; 33(1):201-212. PubMed ID: 34732508
[TBL] [Abstract][Full Text] [Related]
19. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
20. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
